

Author Index

- Abbas, Alexander R., 111
Abraham, Edward, 327
Adams, Henry P., 161
Alsadeq, Ameera, 268
Al-Shami, Amin, 85
Al-Shamkhani, Aymen, 244
Amling, Michael, 223
Appay, Victor, 77
Arora, Ashish, 295
Arron, Joseph R., 111
Axtell, Robert C., 139
- Baldwin, Cynthia L., 379
Banerjee, Sami, 327
Bao, Weili, 102
Barker, David F., 412
Barrett, Bradley S., 306
Barve, Shirish S., 412
Bassil, Ribal, 198
Baumann, Arnaud, 364
Benoit, Stephen, 185
Benson, Micah J., 185
Bergmann, Cornelia C., 285
Bettini, Matthew L., 258
Bevers, Jack, III, 111
Bieniasz, Paul D., 306
Biron, Christine A., 354
Borish, Larry, 41
Bozdagi, Ozlem, 335
Brazowski, Eli, 344
Brock, Guy N., 412
Bruiners, Natalie, 30
Buchan, Sarah L., 244
Buckwalter, Marion S., 139
Buttrick, Thomas, 198
Buxbaum, Joseph D., 335
- Campbell, Daniel J., 120
Candotti, Fabio, 150
Carayanniotis, George, 96
Carayanniotis, Karen, 96
Carlock, Colin I., 161
Carmo, Alexandre M., 391
Cave, Matthew, 412
Cekanaviciute, Egle, 139
Cerovic, Vuk, 400
Chandriani, Sanjay, 111
Charleston, Bryan, 208
Chaudhuri, Jayanta, 252
Chen, Aoshuang, 35
Chen, Chuang, 379
Cheng, Xuhong, 422
Chiang, Nan, 26
Clare, Simon, 439
Collard, Harold R., 111
Constant, Laura, 35
Cook, Tim A., 185
Cordopatis, Paul, 96
Crites, Travis J., 56
Cubillos-Zapata, Carolina, 208
Cui, Huachun, 327
- da Glória, Vânia G., 391
Daley, Stephen, 170
Dalli, Jesmond, 26
Dash, Pradyot, 258
Dave, Sandeep, 295
Davenport, Miles P., 177
David, Jean-Pierre, 223
de Almeida, Sérgio F., 391
de Aquino, Maria Teresa P., 285
Démoullins, Thomas, 364
- Denning, Timothy L., 431
DePianto, Daryle J., 111
Derer, Anja, 223
Dietrich, Hans K., 139
Dkhar, Hedwin Kitdorlang, 295
Dobbins, Jessica, 258
Donovan, Erin E., 85
Douhan, John, III, 185
Du, Sarah, 185
Duan, Lijie, 277
Duhon, Thomas, 120
Dunussi-Joannopoulos, Kyri, 185
- Edmonds, Jason, 185
Egen, Jackson G., 111
Egusquiza, Riann, 139
Elder, Gregory, 335
Elyaman, Wassim, 198
Evavold, Brian D., 68
- Feijóo, Carmen G., 372
FitzGerald, David J., 48
Ford, Laura B., 400
Fragoso, Maria F., 354
Frangieh, Michael, 198
Friedman, David, 102
Fu, Mingui, 327
Fujiwara, Mamoru, 77
Fujiwara, Yuko, 85
- Gagnon, Etienne, 258
Galdames, Jorge A., 372
Gama Sosa, Miguel A., 335
Gao, George F., 77
Gatanaga, Hiroyuki, 77
Geem, Duke, 431
Geng, Yajun, 35
Gennaro, Maria Laura, 30
George, Samantha, 35
Georghiou, Paris E., 96
Getz, Godfrey S., 35
Ghare, Smita S., 412
Ghoreschi, Kamran, 48
Gobejshvili, Leila, 412
Graham, Gerard J., 400
Grey, Shane T., 170
Grimson, Andrew, 177
Grötsch, Bettina, 223
Gudla, Prabhakar R., 56
Guo, Huifang, 130
Gupta, Pawan, 295
Guy, Clifford, 258
Guzman, Efrain, 208
- Ha, Connie, 111
Haase, Ashley T., 277
Halpern, Zamir, 344
Hamm, David E., 258
Hansell, Chris A. H., 400
Harper, Lorraine, 234
Hasenkrug, Kim J., 306
Heilman, Karl J., 306
Hinton, David R., 285
Hobeika, Elias, 268
Hong, Jinsung, 68
Hope, Jayne, 208
Horn, Nikki, 439
Hou, Yuzhu, 130
Hsu, Haoting, 379
Hu, Fanlei, 130
Hu, Jiancheng, 85
Huang, Edward, 13
- Hudgens, Edward, 379
Husain, Solomon, 252
- Jackman, Janet, 111
Jin, Wei, 422
Johnson, Peter W. M., 244
Johnson, R. Paul, 277
Joshi-Barve, Swati, 412
- Kajiwara, Yuji, 335
Kanno, Yuka, 354
Kapil, Parul, 285
Karpman, Diana, 317
Kassiotis, George, 306
Kauder, Steven E., 111
Ke, Hanzhong, 35
Keegan, Sean, 185
Kerr, Jonathan P., 244
Khoury, Samia J., 198
Kläsener, Kathrin, 268
Koh, Amy J., 26
Kolypetri, Panayota, 96
Koni, Pandelakis A., 431
Koshy, Anita A., 139
Kristofferson, Ann-Charlotte, 317
Krogsgaard, Michelle, 56
Kuravi, Sahithi J., 234
Kurdi, Ahmed T., 198
Kuse, Nozomi, 77
- Lakehal, Karim, 30
Leal, Rafaela, 391
Lee, Patricia, 35
Lee, Seung-Hwan, 354
Li, Sam X., 306
Li, Zhanguo, 130
Liberatore, Rachel A., 306
Lin, Haijiang, 130
Lindahl, Gunnar, 317
Liu, Gang, 327
Liu, Lixia, 41
Liu, Zhaoting, 130
Lockett, Stephen J., 56
Lou, Yahuan, 161
Luther, Julia, 223
- Magafa, Vassiliki, 96
Mahajan, Sahil, 295
Martins de Araújo, Mafalda, 391
Masek-Hammerman, Katherine, 277
Matthews, Allysia J., 252
Mayilraj, Shanmugam, 295
McBride, Michelle, 431
McCaulley, Laurie K., 26
McClain, Craig J., 412
McGettrick, Helen M., 234
Medgyesi, David, 268
Medina-Contreras, Oscar, 431
Messer, Ronald J., 306
Messing, Dean, 185
Mielenz, Dirk, 223
Milling, Simon W. F., 400
Modrusan, Zora, 111
Moghe, Akshata, 412
Moreira, Alexandra, 391
Muller, James, 56
Munirathinam, Gnanasekar, 35
- Nakaya, Mako, 422
Nanduri, Ravikanth, 295
N'Diaye, Elsa N., 111
Negri, Julie, 41

- Newberry, Rodney D., 431
 Nibbs, Robert J. B., 400
 Nickerson-Nutter, Cheryl L., 185
 Novak, Jan, 317
- Oda, Shannon K., 85
 Oka, Shinichi, 77
 Olah, Marta, 198
 Olin, Anders I., 317
 Onda, Masanori, 48
 Oravec, Tamas, 85
 Orent, William, 198
 O'Shea, John J., 48, 354
- Padhan, Kartika, 56
 Pan, Yue, 35
 Pappu, Rajita, 111
 Parkesh, Raman, 295
 Parris, Alyson, 439
 Pasmantik-Chor, Metsada, 344
 Pastan, Ira H., 48
 Patil, Madhuvanti, 412
 Payne, Spencer C., 41
 Pelanda, Roberta, 85
 Perkey, Katherine E., 277
 Phares, Timothy W., 285
 Pine, Richard, 30
 Pinello, Jennifer F., 177
 Pryshchep, Sergey, 68
 Pujanauski, Lindsey M., 85
 Puntambekar, Shweta S., 285
 Python, Sylvie, 364
- Qu, Lucy, 277
- Rahman, Shofiur, 96
 Rainger, George Ed, 234
 Ramirez-Carrozzi, Vladimir, 111
 Rankin, Andrew L., 185
 Ravi, Janani, 30
 Reardon, Catherine A., 35
 Rebetz, Johan, 317
 Reeves, R. Keith, 277
 Reth, Michael, 268
 Reyes, Ariel E., 372
 Rodriguez, Varenka, 185
 Rogel, Anne, 244
 Rudd, Brian D., 177
 Ruzek, Melanie, 185
- Sadhukhan, Sanjoy, 150
 Saini, Ankita, 295
 Salamon, Hugh, 30
 Saleem, Moin A., 234
 Salomao, Reinaldo, 327
 Samia-Grinberg, Shany, 344
- Santiago, Mario L., 306
 Santos, Ana Mafalda, 391
 Sarkar, Koustav, 150
 Satchell, Simon C., 234
 Savage, Caroline O. S., 234
 Savarin, Carine, 285
 Schett, Georg, 223
 Schiff, Tamar, 335
 Schinke, Thorsten, 223
 Schmitt, Roland, 317
 Schnute, Mark E., 185
 Serhan, Charles N., 26
 Seth, Nilufer, 185
 Shang, Liang, 277
 Shi, Jianfeng, 130
 Shi, Lanbo, 30
 Shi, Xiaoyun, 130
 Shi, Yi, 77
 Shibolet, Oren, 344
 Shotts, Kristin, 85
 Skoczek, Dagmara A., 439
 Smith, Adrian L., 208
 Smith, Anthony J., 277
 Smith, Norah L., 177
 Sobolewski, Anastasia, 439
 Somavarapu, Arun Kumar, 295
 Southern, Peter J., 277
 Spidale, Nicholas A., 21
 Ståhl, Anne-lie, 317
 Steinke, John W., 41
 Steward-Tharp, Scott, 48
 Stohlman, Stephen A., 285
 Strauch, Pamela, 85
 Summerfield, Artur, 364
 Sun, Hong-Wei, 354
 Sun, Shao-Cong, 422
 Sun, Xiaoming, 77
- Takiguchi, Masafumi, 77
 Tan, Filemon, 161
 Tan, Isaiah, 35
 Tan, Xiaotian, 130
 Tan, Zheng, 327
 Taraban, Vadim Y., 244
 Tarrío, Margarite L., 354
 Tatum, Kiana, 161
 Taylor, Geraldine, 208
 Taylor, Matthew, 150
 Telfer, Janice C., 379
 Teufel, Stefan, 223
 Thakur, Krishan Gopal, 295
 Thannickal, Victor J., 327
 Thomas, Craig, 48
 Thomas, Paul G., 258
 Tigyi, Gabor, 85
 Tisch, Roland, 21
- Torres, Raul M., 85
 Toy, Karen, 111
- Varma, Rajat, 56
 Varol, Chen, 344
 Victorino, Francisco, 85
 Vignali, Dario A. A., 258
 Vignali, Kate M., 258
 Voloudakis, Georgios, 335
 von Schack, David, 185
 Vyas, Yatin M., 150
- Wai, Karen M., 139
 Wakeland, Edward K., 3
 Walczysko, Petr, 439
 Walters, Stacey N., 170
 Wang, Bin, 35
 Wang, Bo, 21
 Wang, Jocelyn, 177
 Wang, Qiang, 130
 Webster, Kylie E., 170
 Wells, Christine Anne, 13
 Wietrefe, Stephen, 277
 Williams, Aaron M., 139
 Williams, Julie M., 234
 Williams, Kurt, 35
 Williams, Mark R., 439
 Willoughby, Jane E., 244
 Wissink, Erin, 177
 Wolters, Paul J., 111
 Wu, Jean, 161
 Wu, Lauren C., 111
 Wucherpfennig, Kai W., 258
- Xie, Na, 327
- Yamaguchi, Ken D., 30
 Yan, Zhaoqi, 35
 Yang, Tao, 130
 Yazdanbakhsh, Karina, 102
 Yu, Jiayi, 422
- Zarnitsyna, Veronika I., 68
 Zhang, Lianfeng, 130
 Zhao, Yong, 130
 Zheng, Guoxing, 35
 Zhong, Hui, 102
 Zhou, Cindy, 161
 Zhou, Xiaofei, 422
 Zhu, Cheng, 68
 Zhu, Linnan, 130
 Zigmund, Ehud, 344
 Zuñiga-Traslaviña, Constanza, 372
 Zupancic, Mary, 277

The Journal of Immunology

Information for Authors

Go to www.jimmunol.org for the most up-to-date instructions.

Editorial Office E-mail: infoji@aai.org
Phone: 301-634-7197 Fax: 301-634-7829

ABOUT THE JOURNAL OF IMMUNOLOGY

Journal Facts:

- Publisher: *The Journal of Immunology* (*The JI*) is owned and published by The American Association of Immunologists, Inc. (AAI)
- Editor-in-Chief: Pamela J. Fink, Ph.D., eic@aai.org
- Editorial Board: *The Journal of Immunology* Editorial Board is included in each issue. All editors are practicing scientists.
- Impact factor: 5.520 (2012 Journal Citation Reports)
- Citations: *The JI* is cited more than any other immunology journal (2012 Journal Citation Reports)
- Number of research articles published/year: 1,278 (2013)
- Number of pages published/year: 13,140 (2013)
- Circulation as of 8/15/13: 3,385
- Over 1.8 million page views per month
- Over 380,000 PDF downloads per month
- Publication schedule: Printed and posted online twice each month
- Issue dates: 1st and the 15th of each month
- Average time from submission to initial decision (full-length manuscripts): 32 days (2012)
- Average time from acceptance to print: 7.4 weeks (2012)
- Acceptance rate: 41% for full-length papers, 15% for Cutting Edge papers (2013)
- Online ISSN: 1550-6606 Print ISSN: 0022-1767

JOURNAL SCOPE AND CONTENT

Full-Length Articles: *The JI* publishes peer-reviewed articles describing novel findings in all areas of experimental immunology, including both basic and clinical studies. Manuscripts are published in the following sections:

Allergy and Other Hypersensitivities
Antigen Recognition and Responses
Autoimmunity
Clinical and Human Immunology
Immune Regulation
Immune System Development
Immunogenetics
Immunotherapy and Vaccines
Infectious Disease and Host Response
Innate Immunity and Inflammation
Molecular and Structural Immunology
Mucosal Immunology
Transplantation
Tumor Immunology

Descriptions of new reagents, research techniques, or clinical case reports usually are appropriate only to the extent they provide innovative insight into unresolved problems or represent major breakthroughs.

The JI will not publish descriptive manuscripts that report the identification of epitopes recognized by B or T cells, unless such identification can be considered of unusual immunological significance. *The JI* usually will not publish the definition of peptide-binding motifs for previously uncharacterized MHC products, regardless of species or method used. Similarly, *The JI* usually will not publish surveys of possible or actual epitopes from pathogens not previously examined for T cell epitopes. Authors should address the immunological significance explicitly and convincingly when submitting a paper that may fall into the above categories. Those wishing to report the identification of epitopes may do so at the Immune Epitope Database and Analysis Resource (<http://www.immuneepitope.org/>).

The JI will consider for publication comparative analysis of proteins of immunological interest (intra- or inter-species comparisons) only if such manuscripts transcend a simple descriptive examination and reveal aspects of significance to evolution and/or function of such proteins that are not intuitively obvious.

The JI will publish manuscripts that describe the characterization of the three-dimensional structure of antibody-defined epitopes, antigen-antibody, or peptide-MHC complexes only if such structures reveal features that are unique in an immunologically relevant manner. *The JI* usually will not publish structures of new MHC allelic products not previously crystallized, homologs from previously uncharacterized species, or peptide-MHC complexes composed of known MHC allelic products but with different peptides. Reports of the three-dimensional structures of allergens or other antigens likewise also fall under this description. The editors consider the atomic structure of antigen-antibody, MHC-peptide, and TCR-MHC complexes sufficiently well established to insist on immunological relevance as a criterion for publication in *The JI*.

Cutting Edge Articles: *Cutting Edge* is the rapid publication section of *The JI*, presenting short reports describing significant advances in an area of immunology. Manuscripts submitted for consideration in this section should present scientifically sound and novel research in a clear and concise fashion and contain conclusions of unusual interest to immunologists that are justified from the data presented. Chief criteria for acceptance are scientific novelty and quality, originality, clarity, and conciseness. In addition to research articles, the *Cutting Edge* section publishes invited brief commentaries on controversial subjects of broad interest to immunologists.

Brief Reviews: *The JI* publishes a small number of invited reviews on a regular basis. These reviews are four to six journal pages in length, including illustrations and references. They cover a focused

area on the advancing edge of immunology and provide a balanced view of current research that can be understood by researchers outside of that specialty. Authors interested in submitting an article to *Brief Reviews* should submit a proposal, including an outline of the proposed review, by e-mail to the Editor-in-Chief at eic@aai.org.

Pillars of Immunology: In the first issue of each month, *The JI* reprints papers regarded as classics in the field. An invited commentary accompanies each reprinted article. Suggestions for significant articles may be made by e-mail to the Editor-in-Chief at eic@aai.org.

In This Issue: A small number of papers regarded by reviewers and editors as the top 10% in their field are highlighted in this section.

Letters to the Editor: The Editor-in-Chief invites brief letters (250 words or less) of general interest, commenting on work published in *The JI* within the previous 3 months. A limited number of letters will be selected for publication. The authors of the original work will be invited to respond, and both the original letter and the authors' response will be published together. If you are interested in commenting on a published paper, e-mail the Editor-in-Chief at eic@aai.org.

Translating Immunology Articles: These invited articles highlight immunological discoveries that have led to a treatment, drug, or diagnostic device.

MANUSCRIPT PREPARATION

Copyright Transfer: All manuscripts are considered to be the property of AAI from the time of submission. Should AAI not publish the paper, AAI releases its rights therein at the time the manuscript is returned to the corresponding author.

Manuscripts published in *The JI* become the sole property of, with all rights in copyright reserved to, AAI.

The corresponding author, on behalf of all authors, signs a copyright transfer form. Authors of articles written as part of their official duties as employees of the U.S. government are exempt from this requirement for transfer of copyright.

Archiving in PMC/Europe-PMC: In March 2011, AAI began a new, free service to authors, to deposit selected manuscripts to PubMed Central (PMC) (*See also Editorial Policies, NIH Public Access Policy*).

Several funding bodies, including the National Institutes of Health (NIH), Howard Hughes Medical Institute (HHMI), Wellcome Trust and Medical Research Council (MRC-UK), mandate that authors deposit published articles into PMC or Europe-PMC. While these mandates apply to authors, not publishers, the new AAI service will help authors comply with these mandates. On behalf of authors who are funded by NIH, HHMI, Wellcome Trust, and MRC-UK, AAI will deposit all manuscripts to NIHMS or Europe-PMC, as applicable, that begin submission to *The Journal of Immunology* after 10AM (EDT) March 29, 2011 and are ultimately accepted for publication; the author must select this option on the online submission form in order for AAI to do so. AAI will deposit the version of the manuscript that has undergone peer review and has been accepted for publication, before copyediting and formatting.

Most funders mandate that articles be made available to the public in PMC at either 6 or 12 months after publication; manuscripts deposited by AAI will comply with these embargo periods. Authors will receive at least two e-mail notifications from PMC about their manuscripts. Authors must respond to both e-mails, in order for the process to be completed.

This free service is not applicable to work that is funded by bodies other than NIH, HHMI, Wellcome Trust, and MRC-UK. Authors funded by other entities that mandate deposition into PMC/Europe-PMC must deposit the accepted version of the manuscript themselves.

How this service works:

- As part of the online submission process, authors select whether or not this service applies to them

- If the manuscript is accepted for publication, AAI will send all files, including Supplemental Data and video files, to NIHMS or Europe-PMC for display in PMC or Europe-PMC
- Authors will receive an e-mail from PMC (NIH/NLM/NCBI) or Europe-PMC to approve the submitted files
- Authors will receive an e-mail from PMC (NIH/NLM/NCBI) or Europe-PMC to approve the XML format
- After final approval by the author, PMC or Europe-PMC will make the manuscript publicly available after the embargo period

Further information is available at <http://www.nihms.nih.gov/help/publishers.shtml>.

Also see *Scientific Publishing Dos and Don'ts for Authors and Reviewers* at http://aai.org/About/Publications/Additional/Docs/AAI_Dos_Donts.pdf

General Guidelines: A 12-point serif font, preferably Times New Roman, is required. Do not use compressed type format. Double-space entire manuscript. Each of the following components should begin on a separate page:

1. The **Title Page** must include the full title; a running title (not to exceed 60 characters); each author's full name as it should be published (first name, middle initial, last name); and the affiliations of all authors and their institutions, departments, or organizations (use the following symbols in this order: *, †, ‡, §, ¶, ||, #, **, ††, ‡‡, §§, ¶¶, ||||, ##). List the phone number, fax number, and e-mail address of the corresponding author on the title page. (See the "Submit Online" section for information about the corresponding author designation during submission and peer review.)

2. The **Abstract** must be 250 words or less for full-length manuscripts. Reference citations should not be included in the *Abstract*. The species of animals or species of origin of cells used in the manuscript must be clearly stated in the *Abstract*. Please ensure that the final few sentences (50 words or less) of the *Abstract* provide a succinct summary of the main point of the paper.

3. The **Introduction, Materials and Methods, Results, and Discussion** sections should begin on separate pages in that order. Do not combine the *Results* and *Discussion* sections for full-length papers.

- For flow cytometry experiments, authors should specify the gating strategies in the *Materials and Methods* or in the figure legend.
- Authors are encouraged to include the Minimal Information About T cell Assays (MIATA) in the *Materials and Methods*, the figure legend, or elsewhere as appropriate.

4. **Acknowledgments** appear immediately after the *Discussion* and before *References*.

5. **Grant support** must not be included in the *Acknowledgments*, but should be cited as a footnote to the title. All funding sources must be disclosed and will be published as a footnote to the title; anonymous or pseudonymous funders are not permitted.

6. **References** must be numbered as they appear in the text. For references with 10 or fewer authors, list the names of all authors. All authors must be listed for each reference. If citations are included in tables or in figure legends, they must be numbered according to the position of citation of the table or figure in the text. Only published papers and papers in press may be included in the *References*. In press articles, i.e., papers not yet published, must be submitted as online attachments in PDF format at the time of article submission. NOTE: Do NOT submit as attachment papers that are already published, e.g., manuscripts published ahead of print. Such papers must be incorporated into the *References* and cited with their DOI numbers and year of publication. Citations of "manuscripts in preparation," "unpublished observations," and "personal communications" must appear parenthetically in the text. Manuscripts "submitted for

publication" (i.e., not yet accepted) also are mentioned parenthetically in the text. Written approval by the persons cited in personal communications must accompany the manuscript unless they are also authors of the manuscript submitted to *The JI*.

Format for references:

Periodicals: Wells, A. D., M. C. Walsh, D. Sankaran, and L. A. Turka. 2000. T cell effector function and anergy avoidance are quantitatively linked to cell division. *J. Immunol.* 165: 2432–2443.

Books: McIntyre, T. M., and W. Strober. 1999. Gut-associated lymphoid tissue: regulation of IgA B-cell development. In *Mucosal Immunology*, 2nd Ed. P. L. Ogra, J. Mestecky, E. Lamm, W. Strober, J. Bienenstock, and J. R. McGhee, eds. Academic Press, San Diego, CA, p. 319–356.

Articles published ahead of print: Fraser, D. A., A. K. Laust, E. L. Nelson, and A. J. Tenner. 2009. C1q differentially modulates phagocytosis and cytokine responses during ingestion of apoptotic cells by human monocytes, macrophages, and dendritic cells. *J. Immunol.* doi:10.4049/jimmunol.0902232.

7. **Footnotes** should be used to designate the source of support, new or special abbreviations used, correspondence address, current address, etc. Footnotes should be numbered consecutively and will appear on the title page, but for submission are grouped together and placed on a separate page between the *References* and the *Figure Legends*.

8. **Abbreviations** that may be used without definition are provided in the Standard Abbreviations list. Spell out nonstandard abbreviations used less than three times. Nonstandard abbreviations used three or more times must be defined in a footnote. Abbreviations and their definitions must be consistent throughout the text.

9. **Tables** must be numbered with Roman numerals in order of appearance in the text. All tables must have a title. Table legends are prepared as footnotes to the table and are included with the table. Tables must be in DOC file format. Each table should be submitted as a separate file.

10. **Figure legends** must be numbered with Arabic numerals in order of appearance in the text and should include a short title after the figure number. Where possible, symbols and patterns used to distinguish data should be defined in a key placed within the graphic rather than in the figure legend. All figure legends must specify the number of times each experiment was independently performed, as well as the number of animals or replicates in each experimental group. For flow cytometry experiments, authors should specify the gating strategies in the *Materials and Methods* or in the figure legend.

11. **Figures** At initial submission, please submit low-resolution files of the smallest possible size that will convey the needed information. Smaller files can be downloaded more quickly by reviewers and will hasten the review process. Alternatively, a single PDF of text plus figures may be submitted at initial submission.

At submission of a revised manuscript, high-resolution figures that meet the following specifications must be submitted. For more information see the TIPS page on the online manuscript submission home page (<http://ji.msubmit.net>).

- **Color:** Color figures must be in the RGB color space.
- **File Sizes:** Figures should not exceed 10 MB (average size is about 2 MB).
- **Image Sizes:** Figures should be submitted in final print publication size (printed 1:1). Figures may be published in print in one of two formats: single column (width from 3.37 to 8.23 cm) or double column (width from 12.65 to 17.1 cm). The single-column format is preferred. Unless the file size is too large, multi-panel figures should be submitted as a single file. Do not draw boxes around figures or figure parts.
- **Text and Lines:** Text in figures must be 6–8 points in size, except for single letter markers, which may be 12 points. Helvetica or

Arial should be used for all figure text (except for the use of symbols). Line widths must be greater than one point thick or they will not be visible on the PDF version of the article.

- **Numbering:** Figures must be numbered as they appear in the text.
- **File Format:** Figures should be in **TIFF** (better for halftone art, e.g., blots, photographs), **EPS** (better for line art or monochrome art, i.e., anything that involves sharply delineated lines), or PDF format. PowerPoint files are not suitable quality, as their resolution is too low for print. Please see http://dx.sheridan.com/guidelines/ms_office.html for detailed instructions on converting PowerPoint files to TIFF files.
- **Guidelines:** For general guidelines for creating digital art, go to <http://dx.sheridan.com/guidelines/main.html>.

12. **Digital Images:** All images submitted to *The Journal of Immunology* must accurately represent the original data. Original data (digital files, autoradiographs, films, etc.) for all experiments should be fully annotated, secured, and retrievable. The original image file (raw data file) should be kept in an unprocessed and noncompressed file format. Figures that are compiled into multi-figure panels should be kept individually.

Although manipulation of images should be kept to an absolute minimum, there are some circumstances when manipulations are necessary. If, however, the quality of an image is too poor to clearly convey the conclusion, the experiment should be repeated.

- **Collecting Images:** If multiple images are compared to one another, collect each image in the same manner. Any post-collection processing should be applied in a uniform manner to all images. If differences in collection/postcollection are necessary, these need to be described in the legend or *Materials and Methods* section.
- **Brightness and Contrast:** If the brightness or contrast of an image needs minor adjustment, adjustments must be applied to the *entire* image and must not obscure or eliminate any information. Significant adjustments are not recommended. Always note any adjustment in the legend or *Materials and Methods* section.
- **Cloning Tools:** Images should not be “airbrushed” (with Clone Stamp Tool/Clone Brush) to remove “blemishes.” Do not use cloning tools to insert something into an image from elsewhere.
- **Gels/Blots:** All gels should contain a positive and a negative control, and a set of molecular weight markers. For Western blots, control panels (actin, GAPDH, etc.) should come from a stripped and reprobed membrane of the experimental blot shown. If this is not possible, the control blots should be derived from the same samples and this should be indicated in the figure legend.
- **Cropping:** Conservative cropping of gels and blots to improve clarity and conciseness may be permitted if the following points are observed:
 - important bands must be retained
 - at least several band widths should be retained above and below the cropped band
 - cropping must be noted in the legend
 - band(s) of interest must be clearly labeled
 - molecular weight marker positions should be shown in all gels/blots
- **Splicing:** Occasionally, images are spliced to rearrange the order of samples for the sake of presentation, such as those in a Western blot. If splicing of data from a single experiment is necessary, draw contrasting (black or white) lines to indicate where the images were joined and state the manipulation in

the legend. It would be preferable to rerun the gel so the order is correct. Images from different experiments should not be spliced to form a new single image.

Cover Art: Cover art is selected from images in accepted articles and changes with each issue of *The JI*. Authors are encouraged to submit color figures with their manuscripts for possible use as cover illustrations. If an image is selected as cover art, the file must have a resolution of at least 300 dpi at a size of 8.5" × 11".

Estimating Manuscript Length: One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, an eight-page, full-length article would contain approximately 64,000 characters. Each line in a table occupies about 60 characters for a single-column table (120 characters for a double-column table). Figures occupy about 180 characters per centimeter height for single-column figures (360 characters for double-column figures). Determine the total character count for the text of your manuscript and add the character-equivalents for the tables and figures. This will provide a reasonable estimate for the printed length of a manuscript.

Web Links in Submitted Manuscripts: Links to Web sites are permitted only if the information contained on the Web site is not essential to the understanding and assessment of the manuscript or to the ability to repeat the experiments described in the paper. Web links will not be checked after submission for correctness or functionality; it is the responsibility of the author to ensure that the web link is correct.

Human and Animal Use: All studies involving human subjects must be conducted in accordance with the guidelines of the World Medical Association's Declaration of Helsinki (most recent revision). All animal studies must be performed in compliance with the U.S. Department of Health and Human Services Guide for the Care and Use of Laboratory Animals (or otherwise equivalent guidelines). A statement that human and/or animal studies have been reviewed and approved by an appropriate institutional review committee must be included in the *Materials and Methods* section of the manuscript.

DEPOSITING IN PUBLIC DATABASES

High-resolution structural data: Any paper submitted to *The JI* that contains new high-resolution structural data requires an accession number from the Protein Data Bank (www.rcsb.org/pdb/Welcome.do) and assurance that unrestricted release will occur at or before the time of publication. The accession number should be accompanied by the Web site address of the databank.

Nucleotide sequences: Sequences of nucleotides or amino acids longer than 50 bases/residues should not be presented in the text or in table form, but rather should be submitted as a publication quality figure. Original nucleotide sequences and determined nucleotide sequences encoding reported amino acid sequences described in the manuscript must be submitted to GenBank (<http://www.ncbi.nlm.nih.gov/Genbank/>) or European Nucleotide Archive (<http://www.ebi.ac.uk/ena/>) at the time of manuscript submission. An accession number and sequence availability are required at the time of publication. The accession number should be accompanied by the Web site address of the databank.

Microarray data: *The JI* will not publish descriptive manuscripts that report microarray data, unless such information can be considered of unusual immunological significance and/or include functional experiments that provide novel insight into mechanism. As with other scientific approaches, current experimental, quantitation, verification, and statistical analyses are expected. Microarray experiments should be Minimum Information About a Microarray Experiment (MIAME) compliant (for guidelines, see <http://www.mged.org/Workgroups/MIAME/miame.html>). Whereas limited on-line space may be available for supplemental tables associated

with the manuscript, complete microarray data must be deposited in the appropriate public database (e.g., GEO [<http://www.ncbi.nlm.nih.gov/geo/>], ArrayExpress [<http://www.ebi.ac.uk/microarray-as/ae/>], or CIBEX [<http://cibex.nig.ac.jp/index.jsp>]), and must be accessible without restriction from the date of publication. An entry name or accession number must be included in the paper before publication. The accession number should be accompanied by the Web site address of the databank.

STYLE GUIDE

General style conventions: In general, *The JI* follows *Scientific Style and Format: The CSE Manual for Authors, Editors, and Publishers, 7th Edition*, published by the Council of Science Editors, Inc., in instances where style issues are not directly addressed.

Abbreviations for references: PubMed (<http://www.ncbi.nlm.nih.gov/journals>) is the primary source for journal name abbreviations.

Nomenclature: The most current links for nomenclature guidelines are posted online.

Allergen nomenclature: Nomenclature for allergens should be assigned in cooperation with the International Union of Immunological Societies (IUIS) Allergen Sub-Committee. Authors of accepted manuscripts that describe novel allergens will be requested to complete a brief standard form available at IUIS Allergen Nomenclature (<http://www.allergen.org/Allergen.aspx>).

CD nomenclature: For the purpose of consistency, *The JI* will follow CD nomenclature. For murine molecules, *The JI* will follow the nomenclature previously published (*J. Immunol.* 160: 3861–3868, 1998). For human molecules, standard CD nomenclature will be followed as updated (*J. Immunol.* 168: 2083–2086, 2002). See also <http://www.HCDM.org>.

Chemical names: The *JI* uses *The Merck Index* (<http://library.dialog.com/bluesheets/html/bl0304.html>) and the *IUPAC-IUB Commission on Biochemical Nomenclature-Chemical Abstracts* (<http://www.chem.qmul.ac.uk/iupac/bibliog/white.html>) as the primary references for proper spelling and style of chemical names.

Chemokine/chemokine receptor nomenclature: The systematic name for chemokines and chemokine receptors should be used. The original name may be given in parentheses if desired. See *Cytokine* 21:48–9, 2003.

Enzyme nomenclature: Enzyme Nomenclature (<http://www.chem.qmul.ac.uk/iubmb/enzyme/>) is *The JI* source for style and spelling of enzyme names.

Gene nomenclature: The HUGO guidelines for gene nomenclature (<http://www.genenames.org/>) may be used for naming human genes. Mouse Genome Informatics (<http://www.informatics.jax.org/>) is a reference source for naming mouse genes.

Genetic nomenclature for mice: *The JI* uses the revisions for standardized genetic nomenclature for mice published periodically in *Mouse Genome*. A current listing of inbred strains of mice and rats is available at Mouse Genome Informatics. Authors are encouraged to deposit their mapping data with the Mouse Genome Database (MGD) (<http://www.informatics.jax.org/>) before publication and to include the assigned MGD accession numbers in their manuscripts. Data may be submitted electronically by e-mail. Information about electronic submission of datasets can be obtained at the Data and Nomenclature Submissions page. Gene symbols should be reserved with MGD in advance of publication. An electronic nomenclature submission form is available from the MGD Web site.

HLA nomenclature: HLA nomenclature is updated periodically by the World Health Organization Nomenclature Committee for Factors of the HLA System. A recent reference is *Hum. Immunol.* 64: 919–20, 2003. Annual comprehensive revisions are published

in *Human Immunology*, usually in the spring. See also: <http://www.ebi.ac.uk/imgt/hla/>.

SUPPLEMENTAL MATERIALS

Supplemental Data:

- Supporting data that are not essential to understanding the material presented in the manuscript may be submitted with the original paper for peer review; however, the print version of the paper must stand on its own without the supplemental material.
- Supplemental material is primarily intended for short videos, large tables, large sequence alignments, or large data sets. Additional supplemental figures and tables that support the interpretation and conclusions drawn in the manuscript may, however, also be submitted for review with the manuscript.
- Supplemental material must be submitted as separate files from the rest of the manuscript during the online submission; select "Supplemental Data" as the "File Type" when uploading the files.
- Apart from videos, all files must be either PDF or Excel file format; multiple PDF files should be combined into a single PDF file.
- For Cutting Edge manuscripts, no more than two supplemental figures and/or tables may be submitted. One of the two allowable Cutting Edge supplemental items can be a description, no more than one page in length, of computational or bioinformatics methods. Methods that are normally found in the body of the article may not be included in this Cutting Edge supplemental item.
- For Full-Length manuscripts, no more than four supplemental figures and/or tables may be submitted.
- Each supplemental figure should comprise no more than a single 8.5" × 11" PDF page, and be large enough to be legible when that page is opened.
- Legends or short explanations must accompany all supplemental figures and videos; no other supplementary text is permitted in full-length manuscripts. Legends should be placed below the corresponding figure in the PDF. Legends for videos should be submitted as a single PDF. Table legends must be prepared as footnotes to the table; all tables must have a title.

*Note: Excel files will be converted to PDFs for the review process only. At publication, the file(s) will be uploaded in the original Excel format.

Videos must be 320 × 480 pixels or smaller for best viewing within a browser. Videos must be no longer than 30 seconds and under 10MB, with no sound or voice-over. Submit videos in MPG or QuickTime format. Change QuickTime file extensions to ".mov" so that Web browsers will recognize the file type and play the movie. Compress videos as much as possible to help control file size. Name videos by order of citation appearance (e.g., video1.mov). Select "Video" as the "File Type" when uploading the files during online submission. Authors will be notified if problems exist with videos as submitted and will be asked to take responsibility for modifications. No editing will be done to videos at the Editorial Office. A legend or short explanation must accompany the video.

Links to the supplemental material will appear in two places in the online journal: in the Table of Contents and in the information box associated with the first page of the full-text article. There will not be any links in the body of the article. In the printed paper, supplemental material will be footnoted the first time mentioned: "The online version of this article contains supplemental material."

Supplemental Materials are posted online as provided by the author. There is a publication charge of \$75 per supplemental figure or table.

CUTTING EDGE MANUSCRIPT PREPARATION

Manuscripts submitted to the *Cutting Edge* section should conform to the *General Guidelines* for full-length manuscripts as well as the additional guidelines below:

1. *Cutting Edge* articles, including figures and references, **must fit within four journal pages**. Authors should estimate the size of figures and tables and limit the text accordingly. One printed page in *The JI* contains approximately 8,000 characters, including spaces. Thus, a four-page *Cutting Edge* article would contain approximately 32,000 characters. The formula for estimating the number of pages is provided in Manuscript Preparation.
2. The *Abstract* is limited to 150 words.
3. The *Materials and Methods* section may be sharply limited, but should be sufficient to allow the evaluation of results and conclusions.
4. Authors may combine the *Results* and *Discussion* sections.

PREPARATION OF THE REVISED MANUSCRIPT

Follow *The JI* Editorial Office instructions contained in the previous decision letter carefully and thoroughly. A revised manuscript not returned within 9 months of the date of the decision letter will be considered a new manuscript and subject to a new, complete review.

Individual manuscript files, files for each figure and table (even if they are unchanged from the previous submission), and a point-by-point reply to all referee comments must be uploaded to the system. The revised manuscript text must be marked to show changes using yellow highlighting (Microsoft Word files preferred). Do not show deletions, because if the manuscript is accepted, this version will be immediately sent for publication. High-resolution figure files must be submitted. Figures must be in **TIFF**, **EPS**, or **PDF** format and prepared as described under *Figures*.

SUBMIT ONLINE

Submit online at ji.msubmit.net.

1. For the initial submission of **Full-Length manuscripts**:
 - Either a PDF of the entire manuscript (text, figures, and tables), or individual manuscript, figure, and table files may be uploaded to the system. If individual files are uploaded, the system then creates a single PDF for review purposes.
2. For **Cutting Edge submissions** and all **revised manuscripts**:
 - Individual manuscript, high resolution figure, and table files must be uploaded to the system. Authors should save copies for themselves of all the files in their original formats.
3. See *Author Instructions* for online submission requirements.
4. See the *Figures* section for help with preparing digital art.
5. *The JI's* online submission system requires browsers where cookies and Javascript are enabled.
6. The system will ask submitters to designate the Corresponding Author.
7. Authors will be offered the option to include their ORCID number.

Who Can be a Corresponding Author?: The Corresponding Author must be the person who has the authority to take responsibility for all obligations related to the manuscript and its submission. These responsibilities include but are not limited to:

1. Ensuring the scientific integrity of the submission;
2. Confirming that all authors have read and concur with the submission of the manuscript;
3. Resolving any authorship disputes;
4. Ensuring that all funding sources are listed in a footnote to the title;
5. Making unique materials available to qualified investigators;
6. Complying with requirements to deposit microarray and other similar datasets in public venues;
7. Confirming that any human and/or animal studies have been approved by an appropriate institutional review committee;
8. Ensuring that all conflicts of interest or financial interests are listed;
9. Confirming that the manuscript is original;
10. Confirming that no part of the manuscript has been previously published, submitted elsewhere, or posted on the Internet;
11. Ensuring that the manuscript contains no fabrications, fraud, or plagiarism;
12. Transferring the copyright interest in the manuscript and all Supplemental Materials to AAI;
13. Maintaining/archiving all data related to the manuscript;
14. Signing the Submission form and the Publication Charges forms.

Someone other than the Corresponding Author may begin online submission of the manuscript (this person can upload the files and enter all required information). However, the Submission and Publication Charges forms **MUST** be completed by the Corresponding Author. If the Submitter is not the Corresponding Author, the submission will move from the Submitter's account to the Corresponding Author's account when the Submitter has completed all parts of the submission except the forms, to enable the Corresponding Author to complete the forms.

Please note that the Corresponding Author is the person who receives and responds to communication from the Editor-in-Chief and Editorial Office during the peer-review process. The designation of Corresponding Author does not refer to the person with whom readers may correspond after an article is published.

After the manuscript has been checked by journal staff, the Corresponding Author will receive an e-mail acknowledging receipt of the manuscript. Please contact infoji@aai.org if you do not receive the acknowledgment e-mail.

PUBLICATION FEES

All publication fees are payable in U.S. dollars. Accepted manuscripts are published only upon commitment by the author(s) or institutional financial officer to pay these charges.

Submission Fee: If the corresponding author is not an **AAI member***, a nonrefundable fee of \$50 per manuscript must be paid by credit card (American Express, MasterCard, or Visa) during the submission process. If payment by credit card is impossible, please contact infoji@aai.org to arrange payment by check (drawn on a U.S. bank). We do not accept cash or purchase orders.

*There is no processing fee for Regular, Associate, Emeritus, or Honorary AAI members in good standing.

Page Charges:

- \$70 per page for up to 8 printed pages in the article
- \$175 for each additional page from 9 to 12 pages
- \$225 for each additional page over 12 pages

Color Charges: Color figures may include multiple color panels. Within 24 hours of receiving page proofs, authors will be notified of the estimated cost of color reproduction via a link in an e-mail from aubilling.djs@sheridan.com. Authors must confirm acceptance of the

charges in writing. Authors should expect that color figures in the accepted paper will be reproduced in color and will incur color charges.

Note that AAI members receive a significant discount on color charges.

- Non-AAI Members: \$650 for each color figure.
- AAI Members: \$450 for each color figure for corresponding authors who are Regular, Associate, Emeritus, or Honorary AAI members in good standing on the date of manuscript acceptance.

Supplemental Material:

- \$75 per supplemental figure or table.

Online Posting Fee: \$150 per published article.

Reprints: Reprints must be ordered in advance of publication. Within 24 hours of receiving page proofs, authors will receive an e-mail directing them to the author billing system. From this site you will be able to order reprints, view the estimated charges for your upcoming article, and make payments electronically. Reprint orders from noncontributors must be directed to the Editorial Office.

THE JI AUTHOR CHOICE OPTION

Authors who wish to make their article freely available immediately upon publication in *The Journal of Immunology* may utilize the *Author Choice* option.

NOTE: Wellcome Trust- or RCUK-funded authors who select this option must complete the CC-BY submission form on the "Electronic Forms" page of the submission system.

The AAI, as standard policy, makes all content in *The Journal of Immunology* available to the public at no cost 12 months after publication (*The JI Online*).

The *Author Choice* option is available for \$2,500 to Corresponding Authors who are Regular, Associate Emeritus, or Honorary AAI members at the time of manuscript acceptance. The *Author Choice* fee for Corresponding Authors who are not members of AAI is \$3,000. The *Author Choice* fee is in addition to other Publication Fees (such as page charges, color charges, and Supplemental Data charges).

Authors may select the *Author Choice* option during resubmission of manuscripts that have been returned for revision; the option is not offered at the first round of review. If the manuscript is accepted on the first round of review, authors will be offered the *Author Choice* option via e-mail before files are sent for copyediting. The *Author Choice* fee will be included in the invoice for Publication Fees.

In addition to being made freely available on *The Journal of Immunology* web site immediately upon publication, AAI will deposit the published version of *Author Choice* articles into PMC for immediate posting there as well as on the PMC mirror sites (Europe-PMC and PMC Canada).

Reuse Terms and Conditions: For articles published under the CC-BY 3.0 license, see <http://creativecommons.org/licenses/by/3.0/>

The American Association of Immunologists, Inc. ("AAI") makes the *Author Choice* articles (collectively, the "Articles") available under the terms and conditions below. By accessing and using the Articles you agree to the following:

1. You may, solely for noncommercial purposes, access, download, copy, distribute and display the Articles, and create derivative works from the Articles, subject to the following restrictions:
 - a. You do not affect the authors' moral rights to the Articles in any way;
 - b. If a third party owns any part of any Article, you are responsible for obtaining permission from the copyright owner to use that portion of the Article;

c. If you use an Article for noncommercial research or educational purposes, you must include the appropriate bibliographic citation (authors, journal, article title, volume, issue, page numbers, DOI, and the link to the definitive published version on www.jimmunol.org);

d. Copyright notices and other disclaimers may not be removed from any Article;

e. Any translation of any Article must include, in a prominent manner, the statement: "This is an unofficial translation of the article that appeared in *The Journal of Immunology*. The American Association of Immunologists, Inc. has not approved this translation"; and

f. Any adaptations of any Article must include, in a prominent manner, the statement: "This is an unofficial adaptation of the article that appeared in *The Journal of Immunology*. The American Association of Immunologists, Inc. has not approved this adaptation."

2. Use of the Articles for any commercial purpose is prohibited.

3. The definitive published version of each Article resides on *The Journal of Immunology* web site, located at www.jimmunol.org. AAI makes the Articles available as-is, and makes no representations or warranties, express or implied, regarding the Articles. In no event shall AAI be liable for any loss or damage arising out of or in connection with the use of, or any information in, any Article.

For permissions other than those listed above, or for articles not published as Author Choice, go to <http://www.aai.org/About/Publications/JI/copyright.html>.

PEER REVIEW INFORMATION

The Process: By submitting a manuscript to *The JI*, the authors agree to subject it to the confidential peer-review process. Editors and reviewers are informed that the manuscript must be considered confidential. After a manuscript is received, it is assigned by the Ph.D. scientists on staff to a specific Deputy Editor and a Section Editor, whose expertise is considered to be appropriate. The Section Editor prepares a list of expert reviewers, which may include some suggested by the staff Ph.D. scientists. Authors can indicate specific individuals whom they would like to have excluded as reviewers. Generally, requests to exclude certain potential reviewers will be honored except in fields with a limited number of experts.

All potential reviewers are contacted individually to determine availability. Manuscript files are sent to at least two expert reviewers. Reviewers are asked to complete the review of the manuscript within 2 weeks and to return a short review form. Based on the reviewers' comments, the Section Editor recommends a course of action and communicates the reviews and recommendations to the Deputy Editor for a final decision.

The Deputy Editor considers the comments made by the reviewers and the recommendation of the Section Editor, selects those comments to be shared with the authors, makes a final decision concerning the manuscript, and prepares the decision letter for signature by the Editor-in-Chief. If revisions of the manuscript are suggested, the Deputy Editor also recommends who should review the revised paper when resubmitted. Authors are informed of the decision by e-mail; appropriate comments from reviewers and editors are appended.

Decisions: There are four categories for initial decisions: accept, accept with minor revision, return for revision, and reject. Some manuscripts are accepted provisionally, pending relatively minor revisions. In this case, the Deputy Editor may conduct the rereview. For many manuscripts, authors are invited to resubmit if revision or additional experimentation can address major cri-

ticisms. Typically, one or more reviewers will then be asked to consider the adequacy of the revisions. *Cutting Edge* papers are allowed only minor revisions because of time constraints. All revised manuscripts are carefully reexamined, and ultimate acceptability is not guaranteed. *The JI* does not provide for an advance determination of the acceptability of a particular manuscript for publication, nor does it promise expedited review of selected manuscripts.

Communication with Authors: To minimize the possibility of misinterpretation or errors in verbal communication, the Editorial Office will provide information, in writing, only to the corresponding author and will not provide extensive details (e.g., exact status of a review or a predicted time to final decision). Deputy Editors do not take calls from authors concerning decisions or other related matters. All such inquiries should be addressed in writing to the Editor-in-Chief, who will discuss concerns with the Deputy Editor. This policy has been established to provide uniformity and fairness when addressing concerns about the review process.

Manuscripts Submitted from the Institution of an Editor: Manuscripts submitted from the institution of any Section or Deputy Editor or the Editor-in-Chief are reviewed by other editors from outside that institution. The Editorial Office ensures confidentiality and equity in reviewing all manuscripts.

Rebuttals: If the authors believe that a serious scientific error occurred during the review, a letter of rebuttal may be sent to the Editor-in-Chief explaining the reasons why the decision should be reconsidered. Letters of rebuttal must be received by the Editor-in-Chief within 6 weeks of the date the decision letter was sent. When appropriate, the matter will be taken up with the initial Deputy Editor, Section Editor, or additional reviewers. Rebuttals that challenge rejections that were based on priority alone are rarely successful, since the assignment of priority is necessarily a matter of opinion. If the authors of a rejected manuscript are able to make new advances that go far beyond the original submission, they will often expedite consideration of their paper through the submission of a completely new manuscript.

The JI Reviewers

Selection: Selection of reviewers is the responsibility of the Section Editor, although the Ph.D. scientists on staff make recommendations to the Section Editor from a database of individuals who have reviewed manuscripts previously. This database includes self-identified areas of expertise as well as information about the perceived usefulness and timeliness of past reviews. Individuals who consistently have provided tardy or unhelpful reviews are removed from the database. Every effort is made to avoid both real and apparent conflicts of interest with respect to research activities or collaborative or personal interactions. Reviewers are asked to withdraw from considering any manuscript in which they identify a conflict that has escaped the attention of the Section Editor.

Scientific Integrity: Information contained in manuscripts is considered confidential and should not be shared or distributed. If necessary, a reviewer can consult with others for an adequate evaluation of the research findings if all individuals involved maintain confidentiality, objectivity, and avoid conflict of interest. AAI is not responsible for acts and conduct by reviewers that are not in accordance with accepted professional standards. Reviewers are asked to be objective in their evaluations and to judge primarily the novelty and soundness of the information presented.

Anonymity: Although reviews are anonymous, all comments should be capable of withstanding public scrutiny. Except in very unusual circumstances, the identity of the reviewers and Section and Deputy Editors involved in the review of any given manuscript is kept confidential.

The *J* Editorial Board: The AAI Council, upon recommendation of the Publications Committee, appoints the Editor-in-Chief for a term of 5 years. Deputy Editors, Section Editors, and Associate Editors are nominated by the Editor-in-Chief and appointed by the Publications Committee. The Editor-in-Chief, the Deputy Editors, and the Section Editors constitute the Editorial Board. Deputy Editors are appointed for variable terms. Section Editors and Associate Editors are appointed for one renewable term of 2 years in most circumstances. Deputy Editors, Section Editors, and Associate Editors are required to be members of AAI. The Editor-in-Chief is responsible for the specific editorial conduct of *The J*. The AAI Publications Committee is responsible for the management and evaluation of *The J* and any other official publications of AAI, subject to the general supervision of the AAI Council.

EDITORIAL POLICIES

Scientific Misconduct: AAI will evaluate the credibility of all allegations of scientific misconduct, e.g., suspected fabrication or falsification of data, double publication, or plagiarism. If the Editor-in-Chief determines that an allegation has merit, s/he will first attempt to address the matter with the Corresponding Author. Should that fail to resolve the situation satisfactorily, the Editor-in-Chief will contact the institution of the Corresponding Author to request an investigation; the Editor-in-Chief may also contact the co-authors and/or the funder(s) of the published research. Until the matter is clarified, no additional submissions by any author of the disputed manuscript or published article will be considered for publication. If scientific misconduct is confirmed by the institution, and no request for retraction is made either by the institution or by any author, the Editor-in-Chief will report his/her findings to a representative of the AAI Publications Committee, and in consultation with a representative of the AAI Council, will decide appropriate action. Only the Corresponding Author, co-authors, and appropriate representative(s) of the relevant institution(s) will be apprised of the status of, or any action(s) taken in response to, allegations of scientific misconduct.

Embargo Policy: For manuscripts considered to be in press or approved for publication, the public release of information should not precede the actual publication of the work. The publication date is defined as the date the first copy is mailed from the printer or the first day the issue is posted full-text online. Please note that the issue date and mail dates do not necessarily coincide. This embargo policy protects the peer-review process and the newsworthiness of the scientific content of published articles, and minimizes the chance for the appearance of misinformation in the lay press. The policy also ensures that scientists have access to all relevant information at the same time as the public. These restrictions do not apply to the presentation of the work at scientific conferences or symposia that precede the actual publication date. Although news reporters may be present at such meetings or symposia, information, tables, or illustrations that in any way duplicate the content of a manuscript submitted for publication or in press should not be provided to reporters by the authors. In particular, press conferences should not be held before the embargo date. The official release of videotape presentations and electronic prepublication of articles on the Internet should adhere to the embargo policy. Violations of these policies are legitimate grounds for withdrawal of the manuscript from publication or other measures that *The J* may choose to take.

Conflict of Interest Disclosures: All funding sources must be disclosed in a footnote to the title; anonymous or pseudonymous funders are not permitted.

Any potential conflict of interest in a submitted manuscript must be disclosed in the "Conflict of Interest" section of the online submission system.

Authors of submitted papers that contain information affecting actual or potential commercial products must declare any conflict of interest or financial interest in the product or in potentially competing products held by them, their spouses, or their minor children. Financial interests include consultancies, employment, service on Board of Directors, honoraria, royalties, research support, grants, or contracts, if any exceed \$5,000 per year in any of the preceding 5 years. They also include expert testimony, or patents received or pending, stock, and equity interests (diversified mutual funds or investment trusts do not constitute competing financial interests). The conflict should be stated briefly on the online manuscript submission screen (e.g., "J.B. Doe has received royalty payments from PQR Incorporated."). It is the responsibility of the corresponding author to review this policy with all authors and to list collectively the relevant relationships.

All disclosures will remain confidential during the review process, but papers accepted for publication will acknowledge conflict of interest and financial interests in a published disclaimer describing the nature of the interests. If authors declare no conflict of interest or financial interests, this also will be noted in a published disclaimer.

NIH Public Access Policy: As of April 7, 2008, the U.S. National Institutes of Health (NIH) requires that manuscripts accepted for publication and that describe research funded in whole or in part with NIH funds be deposited into the NIH PMC repository. Other funding bodies also mandate deposition into PMC.

AAI views this policy as a costly, duplicative effort that diverts federal dollars from biomedical research. For more information about how publishing in *The J* relates to the policy, please see the NIH Public Access Policy: Frequently Asked Questions (<http://publicaccess.nih.gov/FAQ.htm>).

Despite AAI's serious concerns about these policies, AAI has undertaken to help authors comply with them. On behalf of authors who are funded by NIH, AAI will deposit all manuscripts to PMC that begin submission to *The Journal of Immunology* after 10 AM (EDT) March 29, 2011, and are ultimately accepted for publication; the author must select this option on the online submission form in order for AAI to do so. AAI will deposit the version of the manuscript that has undergone peer review and has been accepted for publication, before copyediting and formatting.

NIH mandates that articles be made available to the public in PMC at 12 months after publication; manuscripts deposited by AAI will comply with this embargo period. Authors will receive at least two e-mail notifications from PMC about their manuscripts. Authors must respond to both e-mails in order for the process to be completed.

In addition to NIH, a number of additional funding agencies also mandate submission to PMC/Europe-PMC. AAI will also deposit on behalf of authors funded by HHMI, Wellcome Trust, and MRC-UK; for details see *Manuscript Preparation, Archiving in PMC/UKPMC*.

This free service is not applicable to work that is funded by bodies other than NIH, HHMI, Wellcome Trust, and MRC-UK. Authors funded by other entities that mandate deposition into PMC/Europe-PMC must deposit the accepted version of the manuscript themselves.

Authors agree not to deposit the manuscript to any other repository (except a thesis repository if required), agency, or entity.

Other Funding Agencies: Authors funded by agencies that mandate submission to PMC with public access within 6 months after publication must sign the 6 mth-PMC Submission Form during the online submission process.

Prior Publication: Submission of a manuscript to *The JI* implies that the content has not been published previously and will not be submitted for publication elsewhere while the manuscript is under review. *The JI* considers research results (excluding abstracts and student dissertations) to have already been published if they are publicly available with a fixed content (i.e., content is in an unalterable form) and are citable in any language.

Previous publication of a particular figure may not prevent subsequent publication in *The JI* if that figure is essential to the submitted paper and does not constitute the major contribution. Previously published portions of a paper must be accompanied by a permission release from the copyright holder and must be cited.

Preprints, whether paper copies or noncitable postings on a publicly accessible Web site, are not considered publications, nor are poster presentations of work at a conference.

An invited paper published in a non-peer-reviewed journal, however, would be considered a prior publication.

Submissions of previously published research, as defined by the criteria, must contain a disclosure statement; it is at the Editor-in-Chief's discretion whether to allow peer review of the work in these instances.

Unique materials: It is required that unique materials developed for manuscripts published in *The JI*, that are not available from commercial suppliers, will be made available, within reason, to qualified investigators for their own noncommercial use. An agreement to this effect is included in the Manuscript Submission Form. A reasonable amount may be charged by authors to cover preparation and shipping of the requested material. Any restrictions on sharing of materials (for example, Material Transfer Agreements or patents) that apply to unique materials developed for the manuscript must be disclosed in the *Materials and Methods* section of the paper.

STANDARD ABBREVIATIONS

The abbreviations listed here are used without definition in articles published in *The JI*. The form may be used for both singular and plural, or made plural with "s" at the author's option.

Å, angstrom
 aa, amino acid (only with numbers)
 Ab, antibody
 ABTS, 2,2'-azinobis(3-ethylbenzthiazoline-6-sulfonic acid)
 ADP, adenosine 5'-diphosphate
 Ag, antigen
 AIDS, acquired immunodeficiency syndrome
 AMP, adenosine 5'-monophosphate
 ANOVA, analysis of variance
 AP-1, activator protein 1
 APC, Ag-presenting cell
 ATP, adenosine triphosphate
 BALB/c, a mouse strain
 BALT, bronchus-associated lymphoid tissue
 BAPTA-AM, 1,2-bis(2-aminophenoxy)ethane-*N,N,N',N'*-tetraacetic acid acetoxymethyl ester
 BCR, B cell receptor
 bp, base pair (only with numbers)
 BrdU, 5-bromo-2'-deoxyuridine
 BSA, bovine serum albumin
 C, complement
 C region, constant region of Ig
 cAMP, cyclic AMP
 C terminus, carboxyl terminus
 C-terminal, carboxyl-terminal
 CCL, CC chemokine ligand
 CCR, CC chemokine receptor

CD40L, CD40 ligand
 cDNA, complementary DNA
 CDP, cytidine 5'-diphosphate
 CDR, complementarity determining region
 C/EBP, CCAAT/enhancer-binding protein
 CFA, complete Freund's adjuvant
 CFSE, 5-(and 6-)-carboxyfluorescein diacetate succinimidyl ester
 CFU, colony-forming unit
 cGMP, guanosine 3',5'-cyclic monophosphate
 CHAPS, 3-[(3-cholamidopropyl)dimethylammonio]-1-propanesulfonate
 Ci, curie
 CIITA, class II transactivator
 CLIP, class II-associated invariant-chain peptide
 cM, centiMorgan(s)
 CMP, cytidine 5'-monophosphate
 CMV, cytomegalovirus
 CNS, central nervous system
 CoA, coenzyme A
 Con A, concanavalin A
 CpG, cytosine guanine dinucleotide
 cpm, counts per minute
 CREB, cAMP response binding protein
 cRNA, complementary RNA
 CSF, colony-stimulating factor
 CTL, cytotoxic T lymphocyte
 CTLA, cytolytic T lymphocyte-associated Ag
 CTP, cytidine 5'-triphosphate
 CXCL, CXC chemokine ligand
 CXCR, CXC chemokine receptor
 d, deoxy; distilled (as in dH₂O)
 D region, diversity region of Ig or T cell receptor for Ag
 Da, dalton (only with numbers)
 DAPI, 4',6'-diamidino-2-phenylindole
 DEAE, diethylaminoethyl
 df, degrees of freedom
 DMEM, Dulbecco's modified Eagle's medium
 DMSO, dimethylsulfoxide
 DNA, deoxyribonucleic acid
 DNase, deoxyribonuclease
 DNP, dinitrophenyl
 dpm, disintegrations per minute
 ds, double-stranded (as dsDNA)
 DTT, dithiothreitol
 E, erythrocyte
 EBV, Epstein-Barr virus
 EC₅₀, 50% effective concentration
 ECL, enhanced chemiluminescence
 ED₅₀, 50% effective dose
 EDTA, ethylenediaminetetraacetic acid
 EGTA, ethylene glycol-bis(β-aminoethyl ester)-*N,N,N',N'*-tetraacetic acid
 ELISA, enzyme-linked immunosorbent assay
 ELISPOT, enzyme-linked immunospot
 EMSA, electrophoretic mobility shift assay
 ERK, extracellular signal-regulated kinase
 E:T ratio, effector to target ratio
 Fab, Ag-binding fragment
 F(ab')₂
 F-actin, filamentous actin
 FACS, fluorescence-activated cell sorting
 FAM, 6-carboxyfluorescein
 FBS, fetal bovine serum

- FcR, Fc receptors (e.g., Fc γ RI)
 FCS, fetal calf serum
 FITC, fluorescein isothiocyanate
 FLICE, Fas-associated death domain-like IL-1 β -converting enzyme
 FLIP, FLICE inhibitory protein
 FLT3, *fms*-related tyrosine kinase 3
 fMLF, formyl-methionyl-leucyl-phenylalanine
 fura 2-AM, fura 2-acetoxymethyl ester
 g, gram (only with numbers)
 GALT, gut-associated lymphoid tissue
 GAPDH or G3PDH, glyceraldehyde-3-phosphate dehydrogenase
 G-CSF, granulocyte CSF
 GDP, guanosine 5'-diphosphate
 GFP, green fluorescent protein
 GM-CSF, granulocyte-macrophage CSF
 GMP, guanosine 5'-monophosphate
 gp, glycoprotein (e.g., gp100)
 GPI, glycosylphosphatidylinositol
 GST, glutathione S-transferase
 GTP, guanosine 5'-triphosphate
 h, hour (only with numbers)
 H chain, heavy chain
 H&E, hematoxylin and eosin
 HBSS, Hanks' balanced salt solution
 HEPES, *N*-2-hydroxyethylpiperazine-*N'*-2-ethanesulfonic acid
 HIV, human immunodeficiency virus
 HLA, human histocompatibility leukocyte Ag
 HPLC, high performance liquid chromatography
 HRP, horseradish peroxidase
 HSV, herpes simplex virus
 HUVEC, human umbilical vein endothelial cell
 IC₅₀, 50% inhibition/inhibitory concentration
 ICAM, intercellular adhesion molecule
 ICOS, inducible costimulator
 Id, idiotype; idiotypic determinant
 ID₅₀, 50% infective dose or 50% inhibiting dose
 IDO, indoleamine 2,3-dioxygenase
 IFA, incomplete Freund's adjuvant
 IFN, interferon (e.g., IFN- γ)
 Ig, immunoglobulin
 IgH, Ig heavy chain
 I κ B or I- κ B, inhibitory NF- κ B
 IL, interleukin (e.g., IL-2)
 i.m., intramuscular
 IMDM, Iscove's modified Dulbecco's medium
 IMEM, Iscove's minimal essential medium
 i.p., intraperitoneal
 ITAM, immunoreceptor tyrosine-based activation motif
 ITIM, immunoreceptor tyrosine-based inhibitory motif
 IU, international unit
 i.v., intravenous
 J region, joining region of Ig or T cell receptor for Ag
 JAK or Jak, Janus kinase
 JNK, c-Jun N-terminal kinase
 kb, kilobase (only with numbers)
 kbp, kilobase pair (only with numbers)
 K_a , association constant
 K_d , distribution coefficient; dissociation constant
 K_D , affinity constant
 kDa, kilodalton (only with numbers)
 L chain, light chain
 LD₅₀, 50% lethal dose
 LFA, leukocyte (lymphocyte) function-associated Ag
 LIF, leukemia inhibitory factor
 LPS, lipopolysaccharide
 LU, lytic unit
 2-ME, 2-mercaptoethanol
 mAb, monoclonal Ab
 2-ME, 2-mercaptoethanol
 MACS, magnetic-activated cell sorting
 MALDI, matrix-assisted laser desorption ionization
 MALDI-TOF, matrix-assisted laser desorption ionization-time of flight
 MALT, mucosa-associated lymphoid tissue
 MAPK, mitogen-activated protein kinase
 MCP, monocyte chemoattractant protein
 M-CSF, macrophage CSF
 2-ME, 2-mercaptoethanol
 MEK, mitogen-activated protein kinase kinase
 MEM, minimum essential medium
 MES, 2-(*N*-morpholino)ethanesulfonic acid
 mg, milligram (only with numbers)
 MHC, major histocompatibility complex
 min, minute (only with numbers)
 MIP, macrophage-inflammatory protein
 ml, milliliter (only with numbers)
 MLC, mixed lymphocyte culture
 MLR, mixed leukocyte reaction
 mo, month(s) (only with numbers)
 MOPS, 4-morpholinepropanesulfonic acid
 M_r , relative molecular mass
 mRNA, messenger RNA
 MTT, 3-(4,5-dimethylthiazol-2-yl)-2,5-dimethyltetrazolium bromide
 μ g, microgram (only with numbers)
 μ l, microliter (only with numbers)
 m.w., molecular weight
 MyD88, myeloid differentiating factor 88
n, number in study or group
 NAD, nicotinamide adenine dinucleotide
 NADH, reduced NAD
 NaDodSO₄, sodium dodecyl sulfate
 NADP, NAD phosphate
 NADPH, reduced NAD phosphate
 NBT, nitroblue tetrazolium
 ND, not determined
 NDP, nucleoside 5'-diphosphate
 NF, nuclear factor
 NFAT or NF-AT, nuclear factor of activated T cells
 NF- κ B, nuclear factor κ B
 Ni-NTA, nickel-nitrilotriacetic acid
 NK cell, natural killer cell
 NMP, nucleoside 5'-monophosphate
 NO, nitric oxide
 NOD, nonobese diabetic
 NS, not significant
 nt, nucleotide (only with numbers)
 N-terminal, NH₂-terminal or amino-terminal
 N terminus, NH₂ terminus or amino terminus
 NTP, nucleoside 5'-triphosphate
 OCT, octamer-binding factor
 OD, optical density
 OVA, ovalbumin
p, probability
 PAGE, polyacrylamide gel electrophoresis
 PBL, peripheral blood lymphocyte

- PBMC, peripheral blood mononuclear cell
 PBS, phosphate-buffered saline
 PCR, polymerase chain reaction
 PE, phycoerythrin
 PECAM-1, platelet endothelial cell adhesion molecule-1
 PerCP, peridinin chlorophyll protein
 PFU, plaque-forming unit
 PG, prostaglandin
 PHA, phytohemagglutinin
 PI3K, phosphatidylinositol 3-kinase
 PIPES, piperazine-*N,N'*-bis(2-ethane sulfonic acid)
 PMA, phorbol myristate acetate
 PMSF, phenylmethylsulfonyl fluoride
 PWM, pokeweed mitogen
 r, recombinant (e.g., rIFN- γ)
 R, receptor (e.g., IL-2R)
 RACE, rapid amplification of cDNA end
 RAG, recombination-activating gene
 RANTES, regulated upon activation, normal T cell expressed and secreted
 RBC, red blood cell
 RFLP, restriction fragment length polymorphism
 RIA, radioimmunoassay
 RNA, ribonucleic acid
 RNase, ribonuclease
 rpm, revolutions per minute
 RPMI, (usually RPMI 1640)
 rRNA, ribosomal RNA
 RT-PCR, reverse transcriptase polymerase chain reaction
 s, second (use only with numbers)
 s.c., subcutaneous
 SCID, severe combined immunodeficiency
 SD, standard deviation
 SDS, sodium dodecyl sulfate
 SDS-PAGE, sodium dodecyl sulfate-polyacrylamide gel electrophoresis
 SE, standard error
 SEM, standard error of the mean
 SHIP, src homology 2-containing inositol 5'-phosphatase
 SIV, simian immunodeficiency virus
 sp. act., specific activity
 SRBC, sheep red blood cell
 ss, single-stranded (e.g., ssDNA)
 SSC, standard saline citrate
 STAT, signal transducer and activator of transcription
 SV40, simian virus 40
 $t_{1/2}$, half-life, half-time
 TAMRA, 5-(and 6)-carboxytetramethylrhodamine
 TAP, transporter associated with Ag processing
 Tat, terminal deoxynucleotidyltransferase
 TBS, Tris-buffered saline
 TBST, TBS with Tween 20
 TCA, trichloroacetic acid
 TCR, T cell receptor for Ag
 TDP, thymidine 5'-diphosphate
 TdT, terminal deoxynucleotidyltransferase
 TGF, transforming growth factor
 Th cell, T helper cell
 TLC, thin layer chromatography
 TLR, Toll-like receptor
 TMP, thymidine 5'-monophosphate
 TNF, tumor necrosis factor
 TNP, trinitrophenyl
 TRAIL, TNF-related apoptosis-inducing ligand
 Tris, tris(hydroxymethyl)aminomethane
 tRNA, transfer RNA
 TTP, thymidine 5'-triphosphate
 TUNEL, Tdt-mediated dUTP nick end labeling
 U, unit (only with numbers)
 UDP, uridine 5'-diphosphate
 UMP, uridine 5'-monophosphate
 UTP, uridine 5'-triphosphate
 UV, ultraviolet
 v/v, volume to volume ratio (%)
 v/w, volume to weight ratio (%)
 V region, variable region of Ig
 VCAM, vascular cell adhesion molecule
 V(D)J or VDJ, variable diversity joining
 VLA, very late activation Ag
 W, watt (only with numbers)
 WBC, white blood cell
 WEHI medium
 wk, week (only with numbers)
 xid, X-linked immunodeficiency
 Zap70, ζ -associated protein 70 (or ζ -chain-associated protein 70)

Keywords

Animals

Human
 Rodent
 Other Animals

Cells

B Cells
 Dendritic Cells
 Endothelial Cells
 Eosinophils
 Mast Cells/Basophils
 Monocytes/Macrophages
 Natural Killer Cells
 Neutrophils
 Stem Cells
 Stromal Cells
 T Cells
 T Cells, Cytotoxic
 Th1/Th2 Cells

Diseases

Autoimmunity
 Diabetes
 EAE/MS

Endotoxin Shock

Graft Versus Host Disease
 Immunodeficiency Diseases
 Rheumatoid Arthritis
 Systemic Lupus Erythematosus

Infections

AIDS
 Bacterial
 Fungal
 Parasitic-Helminth
 Parasitic-Protozoan
 Viral

Molecules

AcutePhase Reactants
 Adhesion Molecules
 Antibodies Antigens/Peptides/Epitopes
 Autoantibodies
 Cell Surface Molecules
 Chemokines
 Complement
 Cytokine Receptors
 Cytokines

Fc Receptors

Lipid Mediators
 Lipopolysaccharide
 MHC
 Nitric Oxide
 Protein Kinases/Phosphatases
 Superantigens
 T Cell Receptors
 Transcription Factors

Processes

Allergy
 Antigen Presentation/Processing
 Apoptosis
 Cell Activation
 Cell Differentiation
 Cell Proliferation
 Cell Trafficking
 Chemotaxis
 Comparative Immunology/Evolution
 Costimulation
 Cytotoxicity
 Gene Rearrangement
 Gene Regulation

Hematopoiesis

Inflammation
 Memory
 Neuroimmunology
 Phagocytosis
 Repertoire Development
 Reproductive Immunology
 Signal Transduction
 Tolerance/Suppression/Energy
 Transplantation
 Tumor Immunity
 Vaccination

Techniques

Gene Therapy
 Molecular Biology
 Transgenic/Knockout Mice

Tissues

Lung
 Mucosa
 Skin
 Spleen & Lymph Nodes
 Thymus



IMMUNOLOGY 2015™

SAVE THE DATE

MAY 8-12, 2015 ERNEST N. MORIAL CONVENTION CENTER NEW ORLEANS, LA



IMMUNOLOGY2015.org